Summary
GlobalData, the industry analysis specialist, has released its new report, “Paget’s disease of Bone – Pipeline Assessment and Market Forecasts to 2017”. The report is an essential source of information and analysis on the global Paget’s disease of Bone market. The report identifies the key trends shaping and driving the global Paget’s disease of Bone market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global Paget’s disease of Bone sector.
Paget’s disease of Bone – Pipeline Assessment and Market Forecasts to 2017
This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.
GlobalData’s analysis reveals that the Paget’s disease of bone market was worth $678m in 2009. It is forecast to exhibit a negative compound annual growth rate (CAGR) of 5% for the next eight years and is expected to reach $463m by 2017. The negative growth rate is primarily attributable to the patent expiry of major approved drugs and a weak pipeline for the indication. Furthermore, a substantial decrease in the prevalence of Paget’s disease of bone will lead to a drop in the global prescription population. The market will witness generic erosion owing to the patent expiry of products such as Actonel Reclast and Miacalcin. The market has been steadily declining over the past few years and this trend is likely to continue
Scope
The report provides information on the key drivers and challenges of the Paget’s disease of Bone market. Its scope includes:
- Annualized global Paget’s disease of Bone market revenues data from 2001 to 2009, forecast for eight years to 2017.
- Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends. Pipeline candidates fall under major therapeutic classes such as Antagonist of Wnt Signaling and osteoclast activity inhibitor.
- Analysis of the current and future competition in the global Paget’s disease of Bone market. Key market player covered is Genta Incorporated.
- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the Paget’s disease of Bone therapeutics market
Reasons to buy
The report will enhance your decision making capability. It will allow you to:
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global Paget’s disease of Bone market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global Paget’s disease of Bone market in future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
- What’s the next big thing in the global Paget’s disease of Bone market landscape? – Identify, understand and capitalize.
